Cardiovascular disease remains one of the leading causes of death worldwide, and high levels of low-density lipoprotein cholesterol, commonly known as LDL-C or “bad cholesterol,” are a major contributor. In a major development for heart health research, Eli Lilly and Company announced encouraging Phase 1b trial results for VERVE-102, an experimental gene editing therapy designed to lower LDL cholesterol with a single treatment.
The investigational therapy demonstrated the ability to reduce PCSK9 protein levels by as much as 88% and lower LDL cholesterol by up to 62% in high-risk patients. Researchers also observed durable effects lasting up to 18 months after one infusion, highlighting the possibility of a long-term or potentially one-time treatment for certain forms of hypercholesterolemia.
Eli Lilly and Company and Verve Therapeutics developed VERVE-102 as an in vivo base editing medicine. The treatment is designed to permanently switch off the PCSK9 gene in the liver, which plays a key role in regulating cholesterol levels.
PCSK9 is a well-known target in cholesterol management. People born with naturally occurring PCSK9 loss-of-function mutations often have significantly lower LDL cholesterol levels and a reduced lifetime risk of coronary heart disease. VERVE-102 aims to mimic this naturally protective effect through advanced gene editing technology.
Unlike traditional cholesterol-lowering medications that require daily pills or frequent injections, VERVE-102 is intended to work after just one intravenous infusion.
The Phase 1b Heart-2 study evaluated adults with heterozygous familial hypercholesterolemia, also called HeFH, or premature coronary artery disease. These patients remained at elevated cardiovascular risk despite existing lipid-lowering therapies.
Researchers tested six dose levels ranging from 0.3 mg/kg to 1.0 mg/kg in 35 participants. Results showed clear dose-dependent reductions in both PCSK9 protein and LDL cholesterol levels.
The average PCSK9 reductions included:
The corresponding LDL cholesterol reductions were:
Importantly, these cholesterol-lowering effects remained durable over time. Some patients maintained results for up to 18 months following a single treatment.
Current cholesterol-lowering therapies, including statins and PCSK9 inhibitors, can be highly effective. However, many patients struggle with long-term adherence due to medication schedules, side effects, or treatment fatigue.
VERVE-102 could represent a completely different approach to cardiovascular care. Instead of lifelong disease management, gene editing therapies may offer a one-time intervention capable of producing lasting cholesterol reduction.
According to Dr. Riyaz S. Patel of Barts Health NHS Trust and University College London, many patients with elevated LDL cholesterol still fail to achieve consistent control despite available treatments. He noted that innovative approaches are urgently needed because coronary artery disease remains a major global health burden.
Safety remains one of the biggest concerns in any gene editing program. In the interim analysis, VERVE-102 appeared to be generally well tolerated across all tested dose levels.
Researchers reported:
The most common side effects included mild infusion-related reactions and fatigue. All participants completed their planned dosing schedule successfully.
Although these findings are encouraging, larger studies will still be necessary to fully understand the long-term safety profile of this experimental therapy.
The U.S. Food and Drug Administration has granted Fast Track designation to VERVE-102 for reducing LDL cholesterol in patients with hyperlipidemia and elevated cardiovascular risk.
Fast Track designation is intended to accelerate the development and review of promising therapies for serious medical conditions. This recognition suggests regulators see meaningful potential in the treatment’s early clinical results.
Heterozygous familial hypercholesterolemia affects approximately 1 in every 200 to 250 people globally. The inherited disorder causes persistently high LDL cholesterol levels from birth and significantly increases the risk of premature cardiovascular disease.
Patients with HeFH often require multiple cholesterol-lowering therapies throughout life, and many still struggle to reach recommended LDL targets.
If future clinical studies confirm the effectiveness and safety of VERVE-102, the therapy could become a groundbreaking option for these high-risk patients.
VERVE-102 uses messenger RNA and guide RNA packaged inside a lipid nanoparticle delivery system. After infusion, the treatment travels to liver cells, where it edits the PCSK9 gene using adenine base editing technology.
The therapy relies on proprietary GalNAc-LNP technology developed by Verve Therapeutics. This delivery system helps target liver cells through specific receptors, improving treatment precision.
Because the liver is the primary source of circulating PCSK9 protein, editing the gene directly in liver cells may provide long-lasting LDL cholesterol reduction.
Lilly plans to begin Phase 2 clinical trials for VERVE-102 before the end of 2026. These larger studies will evaluate additional patients and further examine the therapy’s long-term efficacy and safety.
The company is also advancing other gene editing cardiovascular programs, including VERVE-201, which targets the ANGPTL3 gene for lipid management.
While VERVE-102 is still investigational and not yet approved for public use, the early data provide a glimpse into how gene editing could transform cardiovascular medicine in the future.
Gene editing has already shown promise in rare genetic diseases, but cardiovascular medicine represents a much larger opportunity. Millions of people worldwide live with elevated LDL cholesterol and face ongoing risks of heart attacks, strokes, and coronary artery disease.
A successful one-time treatment that safely delivers durable cholesterol reduction could reshape how doctors manage cardiovascular risk for decades to come.
Although more research is necessary, the Heart-2 trial results position VERVE-102 as one of the most closely watched developments in the rapidly growing field of cardiovascular gene editing.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. VERVE-102 is an investigational therapy that has not yet received regulatory approval for general clinical use. Patients should consult qualified healthcare professionals before making decisions regarding cholesterol management or cardiovascular treatment options.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.